Atara Biotherapeutics submits IND for ATA3219 to treat Lupus Nephriti

Atara Biotherapeutic announced its recent submission of an Investigational New Drug IND application to the U.S. Food and Drug Administration FDA for the use of ATA3219 as a monotherapy for the treatment of systemic lupus erythematosus SLE with kidney involvement upus nephritis . “Despite therapeutic advances, there remains high unmet need in lupus nephritis, where standard of care and approved therapies have limited efficacy that often rely on multi-year, if not lifelong immune suppression,” said Rajani Dinavahi, Chief Medical Officer at Atara. “We are dedicated to advancing medical breakthroughs with innovative cell therapies that truly make a difference. We look forward to working with the FDA to initiate this study and advance ATA3219 into the clinic to potentially bring a new disease-modifying option for patients suffering from this chronic disease.”